Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

Citation

Published Version
doi:10.1038/bcj.2014.23

Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:12153006

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
CORRIGENDUM

Vorinostat in combination with lenalidomide and dexamethasone 
in patients with relapsed or refractory multiple myeloma

DS Siegel1-9,10, P Richardson2,9, M Dimopoulos3, P Moreau4, C Mitsiades1, D Weber5, J Houp6, C Gause6, S Vuocolo6, J Eid6, 
T Graef7 and KC Anderson8

Blood Cancer Journal (2014) 4, e202; doi:10.1038/bcj.2014.23; published online 11 April 2014

Correction to: Blood Cancer Journal (2014) 4, e182; doi:10.1038/
bcj.2014.1; published online 21 February 2014

Since the publication of this article, the authors have identified an error concerning one of the author affiliation addresses. KC 
Anderson was incorrectly affiliated to the following address: 
‘Merck & Co. Inc., Whitehouse Station, NJ, USA’. The correct address details are shown here.

The article has also been rectified, and now carries the correct information.

The Authors would like to apologise for any inconvenience this may have caused.

1Myeloma Division, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA; 2Dana-Farber Cancer Institute, Boston, MA, USA; 3Department of Clinical Therapeutics, University of Athens, Athens, Greece; 4University Hospital, Nantes, France; 5MD Anderson Cancer Center, Houston, TX, USA; 6Merck & Co. Inc., Whitehouse Station, NJ, USA; 7Pharmacyclics Inc., Sunnyvale, CA, USA and 8Department of Medicine, Harvard Medical School and Kraft Family Blood Center, Dana-Farber Cancer Institute, Boston, MA, USA. 
Correspondence: Dr DS Siegel, Myeloma Division, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ 07601, USA.
E-mail: DSiegel@HackensackUMC.org

9These authors contributed equally to this work.

10As corresponding author, Dr Siegel assumes full responsibility for the overall content and integrity of the manuscript.